SBIR Phase I: Detection of Chronic Diseases via Multiplex Analysis of Circulating Metabolites

SBIR 第一阶段：通过循环代谢物的多重分析检测慢性疾病

• 批准号: 2212865
• 负责人: Martin Fuchs
• 金额: $ 25.57万
• 依托单位: METFORA LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2212865&HistoricalAwards=false
• 关键词: SBIR; Phase; Detection; Chronic; Diseases

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel metabolite diagnostic blood test indicative of early-stage diseases including cancer, chronic heart and lung disorders, and diabetes. The technology analyzes specific panels of blood metabolites indicative of changes in cellular function that occur with disease. This technology reduces the diagnostic interval time from years to weeks or days, diminishes misdiagnosis resulting in improper therapy, and has the potential to alter the use of more invasive diagnostic methods such as biopsies, colonoscopies, and heart catheterizations from an exploratory to a confirmatory role. This Small Business Innovation Research (SBIR) Phase I project aims to use specific panels of circulating metabolites measured using mass spectrometry (MS) and analyzed using artificial intelligence to detect chronic disease conditions. Pre-clinical models have demonstrated that alterations in metabolism occur at the stage of mild disease, before overt symptoms become evident. The first specific condition to be evaluated in this project is pulmonary arterial hypertension. The objective is to establish calibrated MS methods with quantified values of multiplexed metabolite panels in a reproducible manner as required for clinical use. Multi-label classifications will also be developed in order to detect and account for various co-morbidities that can affect overall metabolic changes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是一种新型代谢物诊断血液测试，可指示早期疾病，包括癌症、慢性心肺疾病和糖尿病。 该技术分析了表明疾病引起的细胞功能变化的特定血液代谢物组。 该技术将诊断间隔时间从数年缩短至数周或数天，减少了导致治疗不当的误诊，并有可能将活检、结肠镜检查和心导管检查等更具侵入性的诊断方法的使用从探索性角色转变为确认性角色。 该小型企业创新研究 (SBIR) 第一阶段项目旨在利用特定的循环代谢物组，通过质谱 (MS) 测量并使用人工智能进行分析，以检测慢性疾病状况。临床前模型已经证明，代谢的改变发生在轻度疾病阶段，在明显症状变得明显之前。该项目要评估的第一个具体病症是肺动脉高压。目的是根据临床使用的需要，以可重复的方式建立具有多重代谢组定量值的校准 MS 方法。还将开发多标签分类，以检测和解释可能影响整体代谢变化的各种合并症。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查进行评估，被认为值得支持标准。